Background Adaptive Servo-Ventilation (ASV) treats central sleep apnoea (CSA) and/or coexisting obstructive sleep apnoea (OSA). We investigated the effects of treatment with ASV on disease-specific quality of life (QoL) and daytime sleepiness in patient subgroups stratified per treatment indication for ASV.Methods READ-ASV is a prospective, multi-center registry that enrolled 847 patients with a prescription of ASV in clinical routine between Sept 2017 and March 2021. The Functional Outcomes of Sleep Questionnaire (FOSQ) and the Epworth Sleepiness Scale (ESS) were applied at baseline and after a 12 months follow-up.Results 56% of patients used ASV to treat treatment-emergent central sleep apnoea (TE-CSA) and 31% CSA in cardiovascular disease (CSA-CVD). Other indications were CSA in stroke (2%), opioid-induced CSA (1%), unclassified CSA (2%), coexisting OSA-CSA (4%) and OSA (3%). ASV significantly improved FOSQ scores in the TE-CSA, CSA-CVD and stroke subgroups (mean change ± SD: 1.1±2.5, 1.1±2.6 and 1.8±3.2), but not in the other subgroups (Fig 1). ESS scores were improved in TE-CSA, CSA-CVD and OSA (-2.4±4.3, -2.4±4.4 and -1.9±1.8).Conclusions ASV patients with TE-CSA or CSA-CVD experienced a relevant benefit in disease-specific QoL and self-reported daytime sleepiness. In less common indications further research is required to evaluate therapy effects.